Novo Nordisk
The latest news about Novo Nordisk: headlines, AI summaries and the full story from every source.
- Novo Nordisk Announces Two Major Licensing Deals Worth Nearly $4 Billion
- Eli Lilly and Novo Nordisk Develop Amylin-Based Obesity Drugs as Complement or Alternative to GLP-1s
- Regeneron and Novo Nordisk Combination Therapy Reduces Muscle Loss in Study
- Bristol Myers Squibb vs. Novo Nordisk: A Comparative Analysis of Healthcare Stocks for 2026
- Novo Nordisk outlines growth strategy amid Eli Lilly's expanding GLP-1 lead
- Novo Nordisk Stock Falls After Outlining Long-Term Growth Targets
- Eli Lilly and Novo Nordisk Compete Over Next-Phase Obesity Drug Innovations
- Novo Nordisk's Investor Day Fails to Excite Market
- Novo Nordisk Announces New Drug Pipeline Amid Investor Skepticism
- Ascendis Pharma Regains Rights to Metabolic Drug TransCon Semaglutide
- Study Finds Weight-Loss Drugs from Novo Nordisk (NVO) and Eli Lilly (LLY) Effective at Lower Doses
- Eli Lilly Captures Over 30% of New U.S. Patients on Oral Weight-Loss Medications
- Novo Nordisk Shares Drop After Ziltivekimab Heart Drug Trial Fails
- Oral Wegovy Surpasses Eli Lilly's Zepbound as Top-Selling Weight-Loss Drug
- Eli Lilly Aims to Leverage GLP-1 Success for Future Acquisitions
- Eli Lilly Regains Coverage with CVS Health in GLP-1 Market
- Novo Nordisk Stock Faces Challenges Amid Competition and Clinical Setbacks
- Novo Nordisk and Eli Lilly Compete in Oral Weight Loss Drug Market
- First Ozempic Generics Approved in Canada, Seen as Test Case for Novo Nordisk
- Novo Nordisk Faces Pricing Pressure Amid Strong Demand and Competition from Eli Lilly
- Novo Nordisk Reports Strong Q1 Results Driven by Wegovy Weight-Loss Pill
- Canada Approves Second Generic Version of Ozempic
- FDA Proposes Excluding Novo Nordisk and Eli Lilly Weight Loss Drugs from Bulk Compounding List
- Eli Lilly Investors Await Foundayo Launch Data Amid Market Uncertainty
- Novo Nordisk Partners with OpenAI to Accelerate Drug Development
- Pfizer's GLP-1 Drug May Challenge Novo Nordisk and Eli Lilly's Market Dominance
- OpenAI Partners with Novo Nordisk to Accelerate Prescription Drug Development